How's the Capital Raise Going to Work?, page-88

And that is why CHM has the market cap where it is. Its still high risk. But with that risk comes greater reward (or loss).

Those with a lesser risk profile won't be interested until much later in development, when risk has been reduced. But thats at a much larger market cap, and after more dilution due to future CRs.

We have 2 drugs in the clinic at the moment. One of those trials is at no cost to us. A third drug trial has been delayed to help progress the first 2 with funds available.

Clever, strategy, as both the drugs in clinic are novel and will eligible for fast track approval. Good results in either/both trial should lift the shae price, and hdlp with the next CR.

A nes amendment allows drugs to market before the end of a fast track trial. if certain safety and efficacy criteria are met.

The low SOI and volume mean this isnt a trading stock. This is a buy and hold with a medium to long hold time. It will be an emotional roller-coaster of a ride, but dips present opportunity.